Arbor Strengthens Focus on Therapeutics with Key Additions to Leadership Team
July 20, 2021 08:00 ET
|
Arbor Biotechnologies Inc
- Pam Stetkiewicz, Ph.D., Appointed Chief Operating Officer - Kathryn McCabe, Ph.D., Named SVP, Head of Business Development CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Arbor...
Arbor Biotechnologies to Present at the Raymond James Human Health Innovation Conference
June 21, 2021 08:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced today...
Arbor Biotechnologies to Present at the Evercore ISI GenomeRx Emerging Therapeutics Conference and the Jefferies Virtual Healthcare Conference
June 02, 2021 08:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced today...
Arbor Continues to Build Therapeutic Focus with Key Scientific Leaders
May 27, 2021 08:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced today...
Arbor Biotechnologies Names Devyn Smith, Ph.D., as CEO
April 01, 2021 08:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early-stage life sciences company unlocking nature’s genetic diversity to enable revolutionary gene editing...
Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors
March 03, 2021 08:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies announced today the appointment of Mark D. Angelino, co-founder and former Chief Operating Officer of Generation Bio, to...
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
December 23, 2020 08:00 ET
|
Arbor Biotechnologies Inc
The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO of Arbor: “Arbor's differentiated gene editing technologies allow Lonza to manufacture...
Arbor Biotechnologies Announces Issuance of U.S. Patent for CRISPR-Cas13d
September 25, 2019 09:16 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, an early-stage life sciences company, today announced that the United States Patent and Trademark Office (USPTO) has...
Arbor Biotechnologies Selected For MIT STEX25
July 09, 2019 11:52 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., July 09, 2019 (GLOBE NEWSWIRE) -- Arbor Biotechnologies (Arbor), an early-stage biodiscovery company, announced today that it has been selected for STEX25, an MIT Startup Exchange...
Arbor Biotechnologies Announces New Discoveries and Addition to its Board
January 03, 2019 08:58 ET
|
Arbor Biotechnologies Inc
Discovers three new CRISPR-Cas systems, findings published in the journal ScienceAppoints Paul Meister to its Board of Directors CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Arbor...